Biosimilars Market, Europe, Forecast to 2025

A Growing Number of Incentive Policies to Propel Growth in the Next 5–7 Years, with Oncology as the Fastest Adopter

USD 4,950

* Required Fields

USD 4,950

PAY BY INVOICE

Be the first to review this product

Patent expiration and increased use of traditional generic drugs are leading to a shift of focus in the pharmaceutical industry toward investment in specialty drugs and high growth areas such as biosimilars. Expensive biopharmaceuticals are largely used for life-saving disorders such as cancer and diabetes, the incidence of which is increasing with population aging in Europe. Moreover, patent expiry of key product classes and a growing emphasis on cost effectiveness are making governments switch to affordable alternatives. There is thus a tremendous opportunity for biosimilar manufacturers. However, the development of biosimilar drugs is riddled with complexities, from R&D to manufacturing to marketing, and is one of the most expensive propositions in the pharmaceutical industry.

About 30 companies are actively developing biosimilar medicines and are researching on the biosimilar versions of 16 distinct molecules that will lead to greater competition by 2020, with 8 major biologic medicines expected to lose exclusivity by 2020.

The next five years are going to be an interesting period in the biosimilars market as a number of biologic drugs are going to lose their exclusivity. On the one hand, this will significantly reduce costs for patients and health systems, on the other, it will pose challenges for regulators to confirm the similarity of the biosimilar to the original biologic in terms of efficacy and safety. The experience of European healthcare companies has been encouraging in the 10 years since the endorsement of the first biosimilar in the EU.

Pricing and physician awareness and support from the regulatory agencies are expected to be key factors driving success in the biosimilars market. Europe is expected to remain the largest contributor to biosimilars revenue worldwide for the next 5–7 years.

The study analyzes the supply market dynamics and forecasts future revenues for key biosimilars in the European region. It also identifies the six key issues to determine the strategic imperatives for success and growth in this market. Moreover, it includes an in-depth analysis of the biosimilar value chain and the payer and regulatory environment. By assessing the impact of trends, disruptive technologies, and new business models, the study arrives at key visioning scenarios for the biosimilars market in Europe. These will help market participants make strategic decisions, stay ahead of their competitors, and gain a significant share in the market. The study also sheds light on strategic partnerships among companies in the European biosimilars market.

Highlights of the report include:
•     Growth Opportunities and Challenges
•     Supply Market Dynamics
•     Payer and Regulatory Environment Analysis
•     Strategic Imperatives for Success and Growth–The Six Tactical Issues
•     Visioning Scenarios for the Biosimilars Market
•     Business Model Essentials
•     A Macro Overview of the Biosimilars Market

Table of Contents

1. Executive Dashboard
Pharma/Biotech Market—Emerging Trends
Market Snapshot—Biosimilars
Revenue Forecast
Revenue Forecast by Region
Percent Revenue Forecast by Region
Biosimilars Ecosystem—Industry Convergence Map
Ecosystem Partnerships—An Opportunity
Changing Market Scenario—Disruptive Trends
Patent Expiries
Key Regions
Technology Innovation
Global Biosimilars Industry—Six Big Market Themes
2. Growth Environment
Market Overview
Key Challenges in the Biosimilars Market
Market Segmentation by Therapeutic Areas
Trends in the Global Biosimilars Market
Global Biosimilar Patenting Trends
Biosimilars Adoption—Key Determinants
Physician Adoption of Biosimilars—Major Determinants
3. Drivers and Restraints—Total European Biosimilars Market
Drivers and Restraints
Impact Mapping of Drivers and Restraints
4. Growth Opportunity and Market Forecast—Total European Biosimilars Market
Percent Revenue Forecast by Region
Revenue Forecast
Revenue Forecast by Molecule Type
Snapshot—EU Biosimilars Market
Opportunity Heat Map—European Biosimilars Market.
5. Growth Opportunity and Market Forecast of Key Biosimilars—Oncology
Top-selling Biotech Drugs
Growth Opportunities in Oncology
Trastuzumab Biosimilars Adoption Rate
Trastuzumab Biosimilars Patient Population
Trastuzumab Biosimilars
Patient Population Forecast
Pricing and Discounts
Revenue Forecast
Bevacizumab Biosimilars
Adoption Rate
Patient Population
Patient Population Forecast
Pricing and Discounts
Revenue Forecast
6. Growth Opportunity and Market Forecast of Key Biosimilars—Diabetes
Top-selling Biotech Drugs
Growth Opportunities in Diabetes
Insulin Glargine Biosimilars
Adoption Rate
Patient Population
Patient Population Forecast
Pricing and Discounts
Revenue Forecast
7. Growth Opportunity and Market Forecast of Key Biosimilars—Rheumatoid Arthritis
Top-selling Biotech drugs
Growth Opportunities in Rheumatoid Arthritis
Etanercept Biosimilars
Adoption Rate
Patient Population
Patient Population Forecast
Pricing and Discounts
Revenue Forecast
Infliximab Biosimilars
Adoption Rate
Patient Population
Patient Population Forecast
Pricing and Discounts
Revenue Forecast
Adalimumab Biosimilars
Adoption Rate
Patient Population
Patient Population Forecast
Pricing and Discounts
Revenue Forecast
8. Market Challenges—Biosimilars
Challenge 1—Interchangeability
Challenge 2—Innovation in Biologics and Biobetters
9. Supply Market Dynamics—Europe
Future of Biosimilars in Europe
Competitive Landscape Analysis
Market Analysis—Europe
Regional Hot Spots—EU5 Perspective
Country Attractiveness
Biosimilar Uptake in Scandinavia—A Case Study
Key Companies to Watch
Merger, Acquisition, and Partnership Assessment
Biosimilars under Review by EMA
10. Strategic Imperatives and Critical Success Factors for Europe
Payer Environment
Regulatory Environment
Impact of Policies—An EU5 Perspective
Development Process and Technical Requirements
Business Models to Mitigate Concerns over Cost
Strategic Imperatives for Success and Growth
Strategies for Innovators—Case Studies
Strategies for Foreign Participants in the EU
11. Conclusion
Visioning Scenarios for the Biosimilars Market
Business Model Essentials
Competitive Keys for Success in the Biosimilars Market
Legal Disclaimer
12. Appendix
Global Regulatory Landscape
Impact of Regulations in the Biosimilars Market
13. Introduction to Biosimilars
Biosimilars are Not Generics—A Comparison of Generics, Biologics, and Biosimilars
Biologics and Biosimilars—Differences in Manufacturing Processes
Development Process and Technical Requirements for Biosimilars
Timeline for the Development of a Biosimilar Medicine
Value Chain Analysis—Development of a Biosimilar
Market Evolution of Biosimilars, 2015
Comparing the Players—Big Pharma (Innovators), Biotech Firms, and Generic Manufactures
List of Biosimilars Approved in Europe
List of Biosimilars under Review by EMA


List of Figures & Charts

1. Total Biosimilar Market: Key Biologic Patent Losses, Europe, 2004–2021
2. Total Biosimilars Market: Key Trends, Global, 2016
3. Total Biosimilars Market: Major Patent Expiries: Europe and US, 2000–2030
4. Total Biosimilars Market: Key Regions, Global, 2016
5. Total Biosimilars Market: Market Trends, Europe, 2016
6. Total Biosimilars Market: Key Trends and Highlights, Global, 2016
7. Total Biosimilars Market: Biosimilars Adoption, Key Determinants, Global, 2017–2025
8. Total Biosimilars Market: Biologic versus Biosimilar, Global, 2015
9. Total Biosimilars Market: Key Market Drivers and Restraints, Europe, 2017–2025
10. Total Biosimilars Market: Impact Mapping of Drivers and Restraints, Europe, 2017–2025
11. Total Biosimilars Market: Biosimilars Snapshot, Europe, 2017–2025
12. Total Biosimilars Market: Opportunity Heat Map, Europe, 2017–2025
13. Oncology Therapeutic Segment: Top-selling Biotech Drugs, Europe, 2015
14. Oncology Therapeutic Segment: Growth Opportunities, Europe, 2016–2025
15. Oncology Therapeutic Segment: Trastuzumab Biosimilars Adoption Rate, Europe, 2014–2025
16. Oncology Therapeutic Segment: Trastuzumab Patient Population, Europe, 2014 and 2025
17. Oncology Therapeutic Segment: Herceptin® Price and Biosimilars Discount, Europe, 2014–2025
18. Oncology Therapeutic Segment: Bevacizumab Biosimilars Adoption Rate, Europe, 2014–2025
19. Oncology Therapeutic Segment: Bevacizumab Patient Population, Europe, 2014 and 2025
20. Oncology Therapeutic Segment: Avastin® Price and Biosimilars Discount, Europe, 2014–2025
21. Diabetes Therapeutic Segment: Top Selling Biotech Drugs, Europe, 2015
22. Diabetes Therapeutic Segment: Growth Opportunities, Europe, 2016–2025
23. Diabetes Therapeutic Segment: Insulin Glargine Biosimilars Adoption Rate, Europe, 2014–2025
24. Diabetes Therapeutic Segment: Insulin Glargine Biosimilars Patient Population, Europe, 2014 and 2025
25. Diabetes Therapeutic Segment: Lantus Price and Biosimilars Discount, Europe, 2014–2025
26. Rheumatoid Arthritis Therapeutic Segment: Top-selling Biotech Drugs, Europe, 2015
27. Rheumatoid Arthritis Therapeutic Segment: Growth Opportunities, Europe, 2016–2025
28. Rheumatoid Arthritis Therapeutic Segment: Etanercept Biosimilars Adoption Rate, Europe, 2014–2025
29. Rheumatoid Arthritis Therapeutic Segment: Etanercept Biosimilar Patient Population, Europe, 2014 and 2025
30. Rheumatoid Arthritis Therapeutic Segment: Enbrel® Price and Biosimilars Discount, Europe, 2014–2025
31. Rheumatoid Arthritis Therapeutic Segment: Infliximab Biosimilars Adoption Rate, Europe, 2014–2025
32. Rheumatoid Arthritis Therapeutic Segment: Infliximab Biosimilars Patient Population, Europe, 2014 and 2025
33. Rheumatoid Arthritis Therapeutic Segment: Remicade® Price and Biosimilars Discount, Europe, 2014–2025
34. Rheumatoid Arthritis Therapeutic Segment: Adalimumab Biosimilars Adoption Rate, Europe, 2014–2025
35. Rheumatoid Arthritis Therapeutic Segment: Adalimumab Biosimilars Patient Population, Europe, 2014 and 2025
36. Total Biosimilars Market: Key M&A Assessment, Europe, 2015–16
37. Total Biosimilars Market: Key M&A Assessment, Europe, 2015–16
38. Total Biosimilars Market: Key Biosimilars under Review, Europe, 2015–16
39. Total Biosimilars Market: Regulatory Approval Pathway in Europe, 2016
40. Total Biosimilars Market: Impact of Country-level Policies, Europe, 2016
41. Total Biosimilars Market: Strategies for Foreign Participants, Europe, 2016
42. Total Biosimilars Market: Assessing the Future Impact of Trends, Disruptive Technologies, and New Business Models, Europe, 2016–2025
43. Total Biosimilars Market: Comparison of Generics, Biologics, and Biosimilars, Europe, 2016
44. Total Biosimilars Market: Key Trends and Highlights, Global, 2015–2016
45. Total Biosimilars Market: Differences in the Manufacturing Processes of Biologics and Biosimilars, Global, 2015–2016
46. Total Biosimilars Market: Data Requirements for Biosimilar Development, Global, 2016
47. Total European Biosimilars Market: Timeline of Key Events, Global, 2015
48. Total Biosimilars Market: A Comparison of Market Players, Europe, 2016
49. Total Biosimilars Market: List of Biosimilars Approved, Europe, 2016
50. Total Biosimilars Market: List of Biosimilars under Review by EMA, Europe, 2016


1. Total Biosimilar Market: Percent Revenue Forecast by Region, Global, 2016 and 2025
2. Total Biosimilars Market: Revenue Forecast, Global, 2015–2025
3. Total Biosimilars Market: Revenue Forecast by Region, Global, 2015–2025
4. Total Biosimilars Market: Percent Revenue Forecast by Region, Global, 2015–2025
5. Total Biosimilars Market: Impact Mapping of Drivers and Restraints, Europe, 2017–2025
6. Total Biosimilars Market: Percent Revenue Forecast by Region, Global, 2015–2025
7. Total Biosimilars Market: Revenue Forecast, Europe, 2015–2025
8. Total Biosimilars Market: Revenue Forecast by Molecule Type, Europe, 2015–2025
9. Oncology Therapeutic Segment: Trastuzumab Patient Population Forecast, Europe, 2015–2025
10. Oncology Therapeutic Segment: Trastuzumab Revenue Forecast, Europe, 2015–2025
11. Oncology Therapeutic Segment: Bevacizumab Biosimilars Patient Population Forecast, Europe, 2015–2025
12. Oncology Therapeutic Segment: Bevacizumab Biosimilars Revenue Forecast, Europe, 2015–2025
13. Diabetes Therapeutic Segment: Insulin Glargine Biosimilars Patient Population Forecast, Europe, 2015–2025
14. Diabetes Therapeutic Segment: Insulin Glargine Biosimilars Revenue Forecast, Europe, 2015–2025
15. Rheumatoid Arthritis Therapeutic Segment: Etanercept Biosimilars Patient Population Forecast, Europe, 2015–2025
16. Rheumatoid Arthritis Therapeutic Segment: Etanercept Revenue Forecast, Europe, 2015–2025
17. Rheumatoid Arthritis Therapeutic Segment: Infliximab Biosimilars Patient Population Forecast, Europe, 2015–2025
18. Rheumatoid Arthritis Therapeutic Segment: Infliximab Revenue Forecast, Europe, 2015–2025
19. Rheumatoid Arthritis Therapeutic Segment: Adalimumab Biosimilars Patient Population Forecast, Europe, 2015–2025
20. Rheumatoid Arthritis Therapeutic Segment: Adalimumab Revenue Forecast, Europe, 2015–2025
21. Total Biosimilars Market: Percent of Sales, Europe, 2015
22. Total Biosimilars Market: Regional Growth Rates, Global, 2015
23. Total Biosimilars Market: Adoption of Biosimilar Infliximab as a % of the Total Infliximab Market, Scandinavia, 2016
24. Total Biosimilars Market: Timeline for the Development of a Biosimilar Medicine, Global, 2015–2016



Keyword1

Keyword2

Keyword3

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.